The results of its phase I study showed that iruplinalkib had potent antitumor activity and manageable safety profile in crizotinib- or second-generation ALK TKI-resistant, or ALK TKI-naïve patients with ALK- or ROS1-positive advanced NSCLC [13]. Here, ALK is linked to non-small cell lung carcinoma.